Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue...

Descripción completa

Detalles Bibliográficos
Autores principales: Busard, Celine, Menting, Stef, van Bezooijen, Sun-Jine, van den Reek, Juul, Hutten, Barbara, Prens, Errol, de Jong, Elke, van Doorn, Martijn, Spuls, Phyllis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288945/
https://www.ncbi.nlm.nih.gov/pubmed/28148280
http://dx.doi.org/10.1186/s13063-017-1777-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288945/
https://www.ncbi.nlm.nih.gov/pubmed/28148280
http://dx.doi.org/10.1186/s13063-017-1777-y

Ejemplares similares